Bristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs Sales

  • Bristol-Myers Squibb Co BMY joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the year.
  • Today, Merck & Co Inc MRK reported Q1 earnings and sales that trailed Wall Street expectations, citing an early-in-the-year pandemic surge.
  • Yesterday, Amgen Inc AMGN cited the pandemic effect in reporting a drop in its Q1 product sales.
  • BMY reported adjusted EPS of $1.74 missed the analyst consensus estimate of $1.82.
  • Q1 sales of $11.10 billion were roughly in line with the analyst consensus of $11.11 billion, up 3% year-over-year.
  • The pandemic primarily impacted products administered in medical centers, but treatments that could be taken at home remained resilient. According to the statement, excluding pandemic-related buying patterns from the prior year, first-quarter revenue grew 8%.
  • Revenue for Bristol’s Revlimid and Pomalyst, treatments gained through the acquisition of Celgene Inc in 2019 that target multiple myeloma, grew 1% and 8%, respectively, from a year earlier.
  • However, revenue for Opdivo, an immuno-oncology drug used to help treat the skin cancer melanoma, fell 3% Y/Y.
  • The company is awaiting an FDA ruling on the drug’s use in liver cancer patients after failing to improve survival in confirmatory trials.
  • A ruling could come as soon as Thursday, the final day of a three-day FDA oncologic advisory committee meeting.
  • The company has also made advances in expanding its pipeline of new drugs. The FDA has accepted Bristol’s application for Mavacamten, a treatment for symptomatic obstructive hypertrophic cardiomyopathy patients.
  • Guidance: BMY is updating its 2021 GAAP EPS guidance range to $3.18-$3.38 from $3.12-$3.32. Adjusted EPS outlook remains unchanged at $7.35 - $7.55.
  • Price Action: BMY shares are trading 4.1% lower at $63.30 during market trading hours on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceBriefscancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!